Maria Luisa Dupuis

Maria Luisa Dupuis

Auto-generated profile, based on publicly available information

Maria Luisa Dupuis

Pharamcogenetics, Drug Resistance & Experimental Therapeutics Section, Department of Drug Research and Evaluation of Italian National Institute of Health (Istituto Superiore di Sanità), Viale R. Elena 299, 00161 Rome, Italy

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2004 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EPEmiliano Pavoni
Emiliano Pavoni
PVPaola Vaccaro
Paola Vaccaro
APAndrea Pucci
Andrea Pucci
GMGiorgia Monteriù
Giorgia Monteriù
EBElisa Beghetto
Elisa Beghetto
OMOlga Minenkova
Olga Minenkova
Background: Tumor-associated antigens recognized by humoral effectors of the immune system are a very attractive target for human cancer diagnostics and therapy. Recent advances in molecular techniques have led to molecular definition of immunogenic tumor proteins based on their reactivity with autologous patient sera (SEREX). Methods: Several high complexity phage-displayed cDNA libraries from breast carcinomas, human testis and breast carcinoma cell lines MCF-7, MDA-MB-468 were constructed. The cDNAs were expressed in the libraries as fusion to bacteriophage lambda protein D. Lambda-displayed libraries were efficiently screened with sera from patients with breast cancer. Results: A panel of 21 clones representing 18 different antigens, including eight proteins of unknown function, was identified. Three of these antigens (T7-1, T11-3 and T11-9) were found to be overexpressed in tumors as compared to normal breast. A serological analysis of the 21 different antigens revealed a strong cancer-related profile for at least five clones (T6-2, T6-7, T7-1, T9-21 and T9-27). Conclusions: Preliminary results indicate that patient serum reactivity against five of the antigens is associated with tumor disease. The novel T7-1 antigen, which is overexpressed in breast tumors and recognized specifically by breast cancer patient sera, is potentially useful in cancer diagnosis.

24 February 2006 in BMC Cancer
Verified
Journal Article
Open access
EPEmiliano Pavoni
Emiliano Pavoni
MFMichela Flego
Michela Flego
MDMaria Luisa Dupuis
Maria Luisa Dupuis
SBStefano Barca
Stefano Barca
FPFiorella Petronzelli
Fiorella Petronzelli
OMOlga Minenkova
Olga Minenkova
Background: CEA is a tumor-associated antigen abundantly expressed on several cancer types, including those naturally refractory to chemotherapy. The selection and characterization of human anti-CEA single-chain antibody fragments (scFv) is a first step toward the construction of new anticancer monoclonal antibodies designed for optimal blood clearance and tumor penetration.Methods: The human MA39 scFv, selected for its ability to recognize a CEA epitope expressed on human colon carcinomas, was first isolated from a large semi-synthetic ETH-2 antibody phage library, panned on human purified CEA protein. Subsequently, byin vitromutagenesis of a gene encoding for the scFv MA39, a new library was established, and new scFv antibodies with improved affinity towards the CEA cognate epitope were selected and characterized.Results: The scFv MA39 antibody was affinity-maturated byin vitromutagenesis and the new scFv clone, E8, was isolated, typed for CEA family member recognition and its CEACAM1, 3 and 5 shared epitope characterized for expression in a large panel of human normal and tumor tissues and cells.Conclusion: The binding affinity of the scFv E8 is in a range for efficient,in vivo, antigen capture in tumor cells expressing a shared epitope of the CEACAM1, 3 and 5 proteins. This new immunoreagent meets all criteria for a potential anticancer compound: it is human, hence poorly or not at all immunogenic, and it binds selectively and with good affinity to the CEA epitope expressed by metastatic melanoma and colon and lung carcinomas. Furthermore, its small molecular size should provide for efficient tissue penetration, yet give rapid plasma clearance.

1 May 2003 in Chemotherapy
Verified
Journal Article
Closed access
PDF file
MDMaria Luisa Dupuis
Maria Luisa Dupuis
MTMarina Tombesi
Marina Tombesi
MSMarco Sabatini
Marco Sabatini
MCMaurizio Cianfriglia
Maurizio Cianfriglia
Background: P-glycoprotein causing multidrug resistance (MDR) and limiting the efficacy of antineoplastic drugs and protease inhibitors (PIs) is expressed in human CD4+ T lymphocytes, one of the main targets of HIV, in a range of pharmacological barriers and at varying degrees in non-Hodgkin’s lymphoma and Kaposi’s sarcoma. Methods: The differential effect of PIs on P-glycoprotein function was studied by measuring drug efflux inhibition, MDR-reversing ability and MAb UIC2 epitope modulation in MDR variants of the human T lymphoblastoid CEM cell line. Results: The treatment of MDR cells with PIs induces different UIC2 epitope modulations indicating a differential recognition and binding of these antiviral drugs by MDR1 P-glycoprotein. In fact, ritonavir, saquinavir and indinavir act differently to the P-glycoprotein blocker in CEM-VBL10 cells. The MDR level of these cells was markedly affected by ritonavir and saquinavir in the order, while the PI indinavir does not seem to compete with the P-glycoprotein drug transport function. In CEM-VBL100 cells, expressing a very high number of P-glycoprotein molecules, only ritonavir acts as an efficient drug efflux inhibitor and MDR-reversing agent. Conclusion: TheHIV-1 PIs ritonavir and saquinavir even at different levels act as genuine P-glycoprotein substrates by inhibiting dye substrate efflux, modulating UIC2 epitope and reversing drug resistance. Conversely, at least in the in vitrosystem used in the present study, the PI indinavir does not significantly alter P-glycoprotein drug transport activities and function.

1 June 1992 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
SZSilvia Zamboni
Silvia Zamboni
AMAlessandra Mallano
Alessandra Mallano
MFMichela Flego
Michela Flego
AAAlessandro Ascione
Alessandro Ascione
MDMaria Luisa Dupuis
Maria Luisa Dupuis
MCMaurizio Cianfriglia
Maurizio Cianfriglia
We report the genetic construction and expression of a fusion protein between a single chain fragment variable (scFv) human antibody (E8) specific for CEA cell surface antigen and yeast cytosine deaminase (yCD). Sequences encoding for the scFvE8 human monoclonal antibody recognizing an epitope shared by CEACAM1, CEACAM3 and CEACAM5 isoforms were assembled with a monomer of yCD. The construct was placed under the transcriptional regulation of the lac promoter, and in frame with 6xHis tag for protein purification. After transformation and induction of E. coli, the protein was recovered from cell lysates and processed for purification. The scFvE8:yCD fusion protein possessed the binding specificity for melanoma (Mel P5) and colon carcinoma (LoVo) cell lines similar to its cognate human scFv antibody. The scFv8:yCD system showed the ability to render tumor cells susceptible to the far less toxic substrate 5-fluorocytosine (5-FC) by its enzymatic conversion into 5-fluorouracil (5-FU). In vitro pre-treatment of Mel P5 and LoVo cell lines with scFvE8:yCD followed by cell washing and incubation with 5-FC, resulted in significant cell killing supporting the utility of this fusion protein as an agent for tumor-selective prodrug activation. This study shows the feasibility of constructing fusion proteins in a prokaryotic cell based system consisting of a human scFv antibody and yCD to convert the antifungal agent 5-FC to 5-FU, one of the widely used anticancer agent.


1 January 2002
Verified
Journal Article
Closed access
MFMichela Flego
Michela Flego
AAAlessandro Ascione
Alessandro Ascione
APAlessandro Pini
Alessandro Pini
VMVito Mennella
Vito Mennella
MDMaria Luisa Dupuis
Maria Luisa Dupuis
MCMaurizio Cianfriglia
Maurizio Cianfriglia